Vaccine: Fluzone
Company: Sanofi Pasteur
Approval Date: July 2
Protects Against: Influenza

Sanofi Pasteur's Fluzone ranks well above other flu vaccines in terms of sales. In 2012, the product brought in an estimated $1.34 billion in sales. And sales look promising again this year; the company already sold out of four of the 6 different dosages of vaccine due to high demand. The FDA gave the go-ahead for the 2012-2013 influenza vaccine formula just behind several other companies on July 2.

Fluzone also comes as an intradermal product, approved for patients 18 to 64 years old. The needle is 90% shorter and thinner than a traditional needle, reducing pain associated with shots. The tiny needle delivers vaccine into the skin instead of into the muscle.

For more:
Special Report: Top 10 selling flu vaccines of 2012
Sanofi fuels microneedle trend with flu vax
Flu vaccine, Tamiflu shortage as influenza sweeps U.S.


Suggested Articles

AZ's FluMist will be dramatically limited in the U.S. this flu season because of production problems, a spokeswoman said.

As Merck and Pfizer race to market with next-gen vaccines, the companies are fighting in court over a trade secrets lawsuit from Merck.

After working with the government for years to advance a next-gen smallpox vaccine, Bavarian Nordic has finally scored its approval.